Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
 - EconoTimes)
NEW ORLEANS, Sept. 19, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 26, 2017 to file lead plaintiff applications in a securities class action lawsuit against Foundation Medicine, Inc. (NasdaqGS: FMI), if they purchased the Company’s shares between February 26, 2014 and November 3, 2015, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.
Get Help
Foundation Medicine, Inc. investors should visit us for more information about their rights at https://www.claimsfiler.com/cases/view-foundation-medicine-inc-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Foundation Medicine and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the likelihood that the Company would be approved for reimbursement of its tumor tests by Medicare; (ii) the Company’s progress in doing so; (iii) the Company’s robust 2015 financial guidance; (iv) the assumption of Medicare approval on which its 2015 guidance was based; and (iv) as a result of the foregoing, Foundation’s financial statements were materially false and misleading at all relevant times.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
